Immunoprecise Antibodies Stock Today
| IPA Stock | USD 0.38 0.03 7.43% |
Performance0 of 100
| Odds Of DistressOver 81
|
Immunoprecise Antibodies is trading at 0.376 as of the 23rd of November 2024, a 7.43 percent increase since the beginning of the trading day. The stock's open price was 0.35. Immunoprecise Antibodies has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Immunoprecise Antibodies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of January 2017 | Category Healthcare | Classification Health Care |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. The company has 28.83 M outstanding shares of which 666.14 K shares are currently shorted by investors with about 0.73 days to cover. More on Immunoprecise Antibodies
Moving together with Immunoprecise Stock
| 0.72 | ME | 23Andme Holding | PairCorr |
| 0.87 | VALN | Valneva SE ADR | PairCorr |
| 0.62 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Immunoprecise Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immunoprecise Stock Highlights
| President CEO | Jennifer Bath | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Immunoprecise Antibodies Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, HNX Large Cap, HNX Financials, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmunoprecise Antibodies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunoprecise Antibodies' financial leverage. It provides some insight into what part of Immunoprecise Antibodies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunoprecise Antibodies (IPA) is traded on NASDAQ Exchange in USA. It is located in 3204?4464 Markham Street, Victoria, BC, Canada, V8Z 7X8 and employs 72 people. Immunoprecise Antibodies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 10.05 M. Immunoprecise Antibodies runs under Biotechnology sector within Health Care industry. The entity has 28.83 M outstanding shares of which 666.14 K shares are currently shorted by investors with about 0.73 days to cover.
Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Immunoprecise Antibodies Probability Of Bankruptcy
Ownership AllocationImmunoprecise Antibodies has a total of 28.83 Million outstanding shares. Immunoprecise Antibodies retains 12.05 (percent) of its outstanding shares held by insiders and 6.5 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immunoprecise Ownership Details
Immunoprecise Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Xtx Topco Ltd | 2024-06-30 | 12.7 K | |
| Ubs Group Ag | 2024-06-30 | 12.2 K | |
| Mariner Wealth Advisors Llc | 2024-06-30 | 10 K | |
| Simplex Trading, Llc | 2024-06-30 | 7.6 K | |
| Citadel Advisors Llc | 2024-06-30 | 5.1 K | |
| Group One Trading, Lp | 2024-06-30 | 2.4 K | |
| West Paces Advisors Inc | 2024-09-30 | 1.7 K | |
| Citigroup Inc | 2024-06-30 | 7.0 | |
| Susquehanna International Group, Llp | 2024-06-30 | 0.0 | |
| Ingalls & Snyder Llc | 2024-06-30 | 1.3 M | |
| Renaissance Technologies Corp | 2024-09-30 | 60.3 K |
Immunoprecise Antibodies Historical Income Statement
Immunoprecise Stock Against Markets
Immunoprecise Antibodies Corporate Management
| Kari Graber | Vice Services | Profile | |
| Brad McConn | Chief Officer | Profile | |
| Barry Duplantis | VP Relations | Profile | |
| Ilse Roodink | Chief Officer | Profile | |
| David Orton | Chief Officer | Profile | |
| Roland Romijn | Head IPA | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.